EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors

Fabrice Barlesi, Nicolas Isambert, Enriqueta Felip, Byoung Chul Cho, Dae Ho Lee, Julio Peguero, Guy Jerusalem, Nicolas Penel, Esma Saada-Bouzid, Pilar Garrido, Christoph Helwig, George Locke und 2 weitere

The Oncologist · 17.03.2023 · 28 (3) · 258-267

DOI: 10.1093/oncolo/oyac253 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 26.12.2022. Verfasst von Fabrice Barlesi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of the extracellular domain of transforming growth factor beta receptor II (a TGF-β “trap”) fused to a human immunoglobulin G1 monoclonal antibody blocking programmed cell death 1 ligand 1 (PD-L1). We report the efficacy and safety in patients with non-small cell lung cancer (NSCLC) that progressed following anti-PD-(L)1 therapy. Materials and Methods In this expansion cohort of NCT02517398—a global, open-label, phase I trial—adults with advanced NSCLC that progressed following chemotherapy and was primary refractory or had acquired resistance to anti-PD-(L)1 treatment received intravenous bintrafusp alfa 1200 mg every 2 weeks until confirmed progression, unacceptable toxicity, or trial withdrawal. The primary endpoint was best overall response (by Response Evaluation Criteria in Solid Tumors version 1.1 adjudicated by independent review committee); secondary endpoints included safety.

Results

Eighty-three eligible patients (62 [74.7%] treated with ≥3 prior therapies) received bintrafusp alfa. Four patients (3 primary refractory, 1 acquired resistant) had confirmed partial responses (objective response rate, 4.8%; 95% CI, 1.3%-11.9%), and 9 had stable disease. Tumor cell PD-L1 expression was not associated with response. Nineteen patients (22.9%) experienced grade ≥3 treatment-related adverse events, most commonly asthenia (3 [3.6%]) and fatigue, eczema, and pruritus (2 each [2.4%]). One patient had grade 4 amylase increased. One patient died during treatment for pneumonia before initiation of bintrafusp alfa.

Conclusion

Although the primary endpoint was not met, bintrafusp alfa showed some clinical activity and a manageable safety profile in patients with heavily pretreated NSCLC, including prior anti-PD-(L)1 therapy. Tumor responses occurred irrespective of whether disease was primary refractory or had acquired resistance to prior anti-PD-(L)1 therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntineoplastic Agents, ImmunologicalAdultHumansImmune Checkpoint InhibitorsB7-H1 AntigenTransforming Growth Factor betaImmunologic Factors

Stichwörter der Autor:innen

Bintrafusp alfaPD-L1TGF-βbifunctionalnon-small cell lung cancer (NSCLC)

Substanzen

Immune Checkpoint InhibitorsB7-H1 AntigenTransforming Growth Factor betaAntineoplastic Agents, ImmunologicalImmunologic Factors

Autor:innen und Institutionen

  • Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
  • Service d'oncologie médicale CLCC Georges-François Leclerc, Dijon, France.
  • Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), UVic-UCC, IOB-Quiron, Barcelona, Spain.
  • Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Department of Oncology, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Department of Research, Oncology Consultants, Houston, TX, USA.

ORCID-Profile: James L Gulley

Förderung

  • Merck

Zitieren

APA

Barlesi, F., Isambert, N., Felip, E., Cho, B. C., Lee, D. H., Peguero, J., Jerusalem, G., Penel, N., Saada-Bouzid, E., Garrido, P., Helwig, C., Locke, G., Ojalvo, L. S., & Gulley, J. L. (2023). Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors. The Oncologist, 28(3), 258-267. https://doi.org/10.1093/oncolo/oyac253

Vancouver

Barlesi F, Isambert N, Felip E, Cho BC, Lee DH, Peguero J, et al. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors. The Oncologist. 2023;28(3):258-267. doi:10.1093/oncolo/oyac253

BibTeX
@article{Barlesi2023,
  author = {Barlesi, Fabrice and Isambert, Nicolas and Felip, Enriqueta and Cho, Byoung Chul and Lee, Dae Ho and Peguero, Julio and Jerusalem, Guy and Penel, Nicolas and Saada-Bouzid, Esma and Garrido, Pilar and Helwig, Christoph and Locke, George and Ojalvo, Laureen S and Gulley, James L},
  title = {Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors},
  journal = {The Oncologist},
  year = {2023},
  volume = {28},
  number = {3},
  pages = {258--267},
  doi = {10.1093/oncolo/oyac253}
}
Kostenlos starten →